



HAL
open science

SEVERE INFUSION REACTIONS TO INFLIXIMAB: ETIOLOGY, IMMUNOGENICITY, AND RISK FACTORS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Casper Steenholdt, Morten Svenson, Klaus Bendtzen, Ole Østergaard
Thomsen, Jørn Brynskov, Mark Andrew Ainsworth

► **To cite this version:**

Casper Steenholdt, Morten Svenson, Klaus Bendtzen, Ole Østergaard Thomsen, Jørn Brynskov, et al.. SEVERE INFUSION REACTIONS TO INFLIXIMAB: ETIOLOGY, IMMUNOGENICITY, AND RISK FACTORS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. *Alimentary Pharmacology and Therapeutics*, 2011, 34 (1), pp.51. 10.1111/j.1365-2036.2011.04682.x . hal-00637801

HAL Id: hal-00637801

<https://hal.science/hal-00637801>

Submitted on 3 Nov 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**SEVERE INFUSION REACTIONS TO INFLIXIMAB: ETIOLOGY,
IMMUNOGENICITY, AND RISK FACTORS IN PATIENTS WITH
INFLAMMATORY BOWEL DISEASE**

Journal:	<i>Alimentary Pharmacology & Therapeutics</i>
Manuscript ID:	APT-0297-2011.R1
Wiley - Manuscript type:	Original Scientific Paper
Date Submitted by the Author:	12-Apr-2011
Complete List of Authors:	Steenholdt, Casper; Herlev Hospital, Dept of Gastroenterology Svenson, Morten; Biomonitor A/S Bendtzen, Klaus; Biomonitor A/S; University Hospital of Copenhagen, Rigshospitalet, Institute for Inflammation Research Thomsen, Ole; Herlev Hospital, Dept of Gastroenterology Brynskov, Jørn; Herlev Hospital, Dept of Gastroenterology Ainsworth, Mark; Herlev Hospital, Dept of Gastroenterology
Keywords:	Crohn's disease < Disease-based, Inflammatory bowel disease < Disease-based, Ulcerative colitis < Disease-based, Biologics (IBD) < Topics, Clinical pharmacology < Topics, Immunology < Topics

1
2 **SEVERE INFUSION REACTIONS TO INFLIXIMAB: ETIOLOGY,**
3
4 **IMMUNOGENICITY, AND RISK FACTORS IN PATIENTS WITH**
5
6 **INFLAMMATORY BOWEL DISEASE**
7
8
9

10
11
12 Steenholdt C¹, Svenson M², Bendtzen K^{2,3}, Thomsen OØ¹, Brynskov J¹, Ainsworth MA¹
13
14
15

16
17
18 ¹ Dept of Medical Gastroenterology, Herlev Hospital, University of Copenhagen, DK
19

20 ² Biomonitor A/S, Copenhagen, DK
21

22 ³ Institute for Inflammation Research, University Hospital of Copenhagen, Rigshospitalet, DK
23
24
25

26
27 Corresponding author
28

29 Casper Steenholdt, MD
30

31
32 Dept of Medical Gastroenterology, Herlev Hospital, University of Copenhagen
33

34 Herlev Ringvej 75
35

36 DK-2730 Herlev
37

38 steenholdt@brygge.dk
39

40 Phone: +45 40529577
41
42
43
44
45

46 Running head: Severe infusion reactions to infliximab in IBD
47
48
49
50

51 Keywords: Inflammatory bowel disease, Crohn disease, ulcerative colitis, safety, acute severe
52
53 infusion reactions, infliximab, TNF, adverse event, anti-drug antibody, IgE.
54
55
56
57

58 Word count (excluding title page, abstract, study highlights) references, figures, and tables):
59

60 3.175 words

ABSTRACT (max 250 words)

Background: Infliximab (IFX) elicits acute severe infusion reactions in about 5% of patients with inflammatory bowel disease (IBD).

Aim: To investigate the role of anti-IFX antibodies (Ab) and other risk factors.

Methods: The study included all IBD patients treated with IFX at a Danish university hospital until 2010 either continuously (IFX every 4-12 weeks) or episodically (reinitiation after >12 weeks). Anti-IFX Ab were measured by radioimmunoassay.

Results: Twenty-five (8%) of 315 patients experienced acute severe infusion reactions. Univariate analysis showed that patients who reacted were younger at the time of diagnosis (19 vs 26 years, $p=0.013$) and at first IFX infusion (28 vs 35 years, $p=0.012$). Furthermore, they more often received episodic therapy (72 vs 31%, $p<0.001$), and logistic regression revealed this as the only significant predictor of reactions (OR 5 [2-13]; $p<0.001$). IFX reinitiation after 6 months intermission further increased the risk (OR 8 [3-20], $p<0.001$). Most reactions ($n=14$, 88%) occurred at 2nd infusion in the 2nd treatment series ($p=0.006$). Anti-IFX IgG Ab were highly positive in 19 of 20 patients (95%) shortly after the reactions (median 84 U/ml). Anti-IFX IgG Ab measured prior to the retreatment series were negative in 7 of 11 patients tested (64%). Anti-IFX IgE Ab were negative in all patients with reactions.

Conclusion: Acute severe infusion reactions were strongly associated with development of anti-IFX IgG Ab, but not with anti-IFX IgE Ab. The risk was particularly high at the 2nd infusion in retreatment series. Negative anti-IFX Ab before reinitiation did not rule out reactions.

INTRODUCTION

Infliximab (IFX) (Remicade, Centocor) is a chimeric mouse-human antibody, which targets tumour necrosis factor (TNF) alpha. IFX has proven highly effective in inducing and maintaining remission in moderate to severe luminal and fistulizing Crohn's disease and ulcerative colitis.¹ Despite its effectiveness, several adverse drug reactions associated with IFX have been identified, such as opportunistic and non-opportunistic infections, skin reactions including malignancies, autoimmunity, and infusion reactions.^{1;2} Infusion reactions to IFX are classified as acute or delayed. Acute infusion reactions appear in 10-40% of patients and are defined as reactions occurring during or within one hour after infusion.²⁻⁴ Delayed infusion reactions occur 1-14 days after infusion in approximately 2% of patients and is commonly associated with myalgias, arthralgias, headache, fever, rash, and fatigue.^{2;4} Acute reactions can be further categorized as mild, moderate, or severe; the latter occurring shortly after start of infusion necessitating immediate stop of the infusion due to ex. hypotension, chest tightness, respiratory distress with dyspnoea, bronchospasm, or laryngeal oedema, urticaria, or rash. Acute mild to moderate reactions are self-limiting and resolve spontaneously after temporary cessation of the infusion or reduction of the infusion rate. These reactions are usually associated with nausea, headache, fever, erythema, and itching.^{2;4;5}

Acute severe infusion reactions to IFX are generally reported in about 5% of IBD patients and constitute a serious clinical problem because of the severity and the subsequent discontinuation of IFX therapy.⁴ It is speculated that the reactions are caused by IFX immunogenicity.^{4;5} However, little is known about the precise mechanisms including the role of anti-IFX antibodies (Ab) as well as risk factors. We aimed at investigating these factors and in particular the potential usefulness of measurements of IgG and IgE anti-IFX Ab to predict infusion reactions.

METHODS

Patients

All IBD patients treated with IFX either continuously (i.e. IFX every 4-12 weeks) or episodically (i.e. reinitiation of IFX after more than 12 weeks without IFX therapy) from January 1999 until October 2010 were included in this single center study. Anti-IFX Ab, including cross reactivity with adalimumab (ADA), were measured before initiation of a new treatment series and/or after an acute severe infusion reaction. Blood samples were routinely obtained from all patients prior to IFX infusions and following an infusion reaction from May 2009 and onward as part of our local drug monitoring program. Before May 2009 samples were obtained sporadically as decided by the treating physician. Some blood samples were analyzed in conjunction with the reactions while others were stored in a biobank and analyzed as part of this study.

Acute severe infusion reactions were retrospectively identified using patient files. Reactions were defined as acute reactions occurring during IFX infusion which were judged severe by the treating physician, and resulting in immediate and permanent discontinuation of IFX and symptomatic treatment with antihistamines and hydrocortisone, and **if necessary** epinephrine.

All patients at our tertiary center were routinely treated with hydrocortisone (100 mg intravenously), cetirizine (10 mg orally), and acetaminophen (1 g orally) 30 minutes prior to administration of IFX to reduce the risk of acute infusion reactions and to prevent development of anti-IFX Ab.⁶ The study was approved by the regional ethics committee.

Serum analyses

Anti-IFX Ab were measured in samples obtained 30 minutes prior to IFX infusion and/or in close connection with acute severe infusion reactions of which the majority of samples were obtained within one hour after the reactions (n=14) while a few were obtained up to nine days

1
2 after the reactions (n=6). Anti-IFX Ab were exploratively assessed in samples from another four
3
4 patients obtained longer time before or after the reactions (from two months prior to reactions up
5
6 to seven years after reactions). Serum was collected after centrifugation of 10 ml blood, and
7
8 stored at minus 80°C until assay. Anti-IFX IgG and IgE Ab, and cross reactivity with ADA, were
9
10 analyzed in the same sample material. All sera were tested under blinded conditions at
11
12
13
14 Biomonitor A/S (Symbion Science Park, Copenhagen, Denmark).
15
16
17

18 *Anti-IFX IgG Ab and cross reactivity with ADA*

19
20 The fact that IFX is an IgG construct consisting only of kappa light-chains makes it possible to
21
22 use anti-human lambda light-chain Ab to distinguish between free drug and drug in complex
23
24 with any class of lambda-containing human immunoglobulin. The anti-IFX IgG assay was
25
26 carried out as previously detailed.⁷⁻⁹ Briefly, 1% serum was added 4,000-5000 cpm/100 microL
27
28 of ¹²⁵I-IFX. After overnight incubation, free and immunoglobulin-bound (any isotype) tracer
29
30 were separated by precipitation with rabbit anti-human lambda Ab (Dako, Glostrup, Denmark).
31
32 Backgrounds were <4% and the inter- and intra-assay variations were below 20 and 10%,
33
34 respectively. The data are given as U/ml based on a laboratory standard. Cross reactivity
35
36 between anti-IFX Ab and ADA was tested by co-incubation of ¹²⁵I-IFX and sample as described
37
38 above with and without IFX at 25 µg/ml and ADA at 50 µg/ml, respectively. The limit for
39
40 positive ADA cross binding was set to 20% of the displaced ¹²⁵I-IFX obtained by the addition of
41
42 IFX.
43
44
45
46
47
48
49
50

51 *Anti-IFX IgE Ab*

52 Ligand binding to IgE was detected using immunoadsorbed IgE, as previously detailed.¹⁰
53
54 Briefly, a constant amount of anti-IgE monoclonal Ab coupled to paramagnetic beads was
55
56 washed and added to 20% serum sample. After overnight incubation, the beads were washed two
57
58 times and ¹²⁵I-IFX was added followed by co-incubation for 14-18 hours. Beads were sampled at
59
60

1
2 intervals during the experiment and assessed with IgE anti-*Betula verrucosa*-positive serum and
3
4 ¹²⁵I-*Betula verrucosa* allergen no. 1 to include a positive control and to ensure the use of an
5
6 optimal anti-IgE activity. The beads were carefully washed before detecting the amount of
7
8 labeled ligand bound to IgE. Background binding was less than 0.5% of cpm added, and the
9
10 lower limit of detection, set at 2x background level, was 0.14 kUa/l assessed from serial dilutions
11
12 of sera testing positive for anti-Betv1 IgE in an ImmunoCAP-system (Phadia, Uppsala,
13
14 Sweden).¹⁰ Specificity was ascertained by lack of cross-binding to 20x surplus of a serum pool
15
16 negative for specific IgE.
17
18
19
20
21
22

23 **Statistical analyses**

24
25 Statistical analyses were done in SPSS version 18 (IBM, Somers, NY, USA). Two sided p-values
26
27 <0.05 were considered significant. Descriptive statistics were calculated as percentages for
28
29 discrete data and medians with range or interquartile range (IQR) for continuous data. Baseline
30
31 variables of patients with IBD were analyzed for association with development of acute severe
32
33 infusion reactions to IFX using univariate analysis (χ^2 and Mann-Whitney test). Variables
34
35 possibly associated with reaction ($p \leq 0.20$) were further evaluated in an unconditional multiple
36
37 logistic regression analysis (enter method; Wald test used for assessing p-values). Potential risk
38
39 variables were predefined as: Disease type, gender, age at diagnosis, age at first IFX infusion,
40
41 disease duration at first IFX infusion, number of infusions, IFX dosing, IFX regimen, days
42
43 between IFX series (not included in the multivariate model because not all patients were treated
44
45 episodically), and concomitant immunosuppression during last IFX series (azathioprine,
46
47 mercaptopurine, methotrexate, cyclosporine). Distribution of reactions during 1st and 2nd IFX
48
49 series was compared using Log Rank test. Frequencies of reactions at different infusion numbers
50
51 were assessed by Fisher's Exact test.
52
53
54
55
56
57
58
59
60

RESULTS

Patients' characteristics

Twenty-five (8%) of 315 IBD patients (218 with Crohn's disease and 97 with ulcerative colitis) experienced an acute severe infusion reaction to IFX. Patients' characteristics are shown in **Table 1**. Clinical manifestations of reactions as noted in the patient files were: Acute severe malaise (100%), severe dyspnoea (60%), chest pain (44%), nausea (36%), universal erythema (32%), tachycardia (24%), chills and perspiration (24%), dizziness (16%), and hypotension (12%). Symptomatic treatment consisted of immediate cessation of IFX infusion, and intravenous infusion of antihistamine (n=22), hydrocortisone (n=6), and epinephrine (n=2). IFX was permanently discontinued in all patients due to the treating physician's overall evaluation of the reactions being severe.

Risk factors

Episodic therapy

Potential risk factors for development of acute severe infusion reactions were initially assessed by univariate analysis (**Table 1**). Patients who had experienced a reaction were significantly younger at time of diagnosis of IBD and at time of first IFX infusion as compared to patients without reaction. Furthermore, patients with reactions more often received episodic therapy than patients without reactions (**Figure 1**). The time period between 1st and 2nd IFX series was significantly longer among episodically treated patients with reaction compared to episodically treated patients without reaction (**Table 1**).

In order to create a multivariate model of potential predictors of infusion reactions, variables associated with reaction with $p \leq 0.2$ (disease, age at diagnosis, age at first IFX infusion, IFX regimen) were subjected to multiple logistic regression analysis. Episodic IFX therapy was

1
2 identified as the only variable associated with development of acute severe infusion reactions;
3
4 OR 4.9 [1.9-12.5], $p < 0.001$ (**Figure 1**).

5
6
7
8
9 There is no official definition of episodic IFX therapy. Therefore, we investigated whether our
10 findings depended on our definition of episodic therapy. Interestingly, the markedly increased
11 risk observed during episodic therapy, was also evident in a sensitivity analysis where episodic
12 therapy was defined as reinitiation of IFX after minimum 4 months without therapy; OR 5.5
13 [2.2-14.1], $p < 0.001$ (18 reactions among 101 episodically treated patients, and 7 reactions among
14 214 continuously treated patients). Defining episodic therapy as minimum 6 months without IFX
15 further increased risk of reaction during episodic therapy to OR 7.7 [3.0-19.5], $p < 0.001$ (17
16 reactions among 75 episodically treated patients, and 8 reactions among 240 continuously treated
17 patients).

31 32 33 *Number of infusions*

34
35 A significant difference between distribution of reactions during 1st and 2nd IFX series was
36 observed ($p < 0.0001$) (**Figure 2**). Eighteen reactions were observed during episodic IFX therapy:
37 Sixteen occurred during the 2nd IFX series and 14 (88%) of these appeared at the 2nd infusion;
38 thus, 19% of the 2nd infusions in 2nd IFX series resulted in reactions. **The proportion of reactions**
39 **at 2nd infusion was significantly higher than the proportion of reactions at other infusion time**
40 **points during the 2nd IFX series ($p = 0.006$). In contrast, there were no infusion time points**
41 **associated with increased proportion of reactions among continuously treated patients (Figure**
42 **2).**

Anti-drug antibodies

Anti-IFX IgE Ab

Anti-IFX IgE Ab were measured in close connection with acute severe infusion reactions in 20 patients and all tests were negative despite the assay being able to detect even small amounts of IgE Ab against a birch pollen positive control. In another four patients, anti-IFX IgE Ab were exploratively measured in samples obtained longer time before or after the reactions (from two months prior to reactions up to 7 years after reactions with multiple assessments per patient).

Anti-IFX IgE Ab were negative also in these patients. As false negative results can occur if anti-IFX IgE Ab are bound to IFX at the time of testing, we measured anti-IFX IgE Ab at multiple time points in 15 patients (median number of assessments 3, IQR 2-4; IQR 7 days before reaction to 35 days after reaction). Again, all tests were negative.

Anti-IFX IgG Ab

Anti-IFX IgG Ab were highly positive in 19 of 20 patients (95%) after the reactions (median 84 U/ml, IQR 30-100; **Figure 3**). Anti-IFX IgG Ab were undetectable in the four patients in whom explorative samples had been obtained longer time before or after the reactions as previously described. In the majority of patients with reactions during episodic therapy, anti-IFX IgG Ab measured prior to initiation of the new treatment series were negative (seven of eleven patients; **Figure 3**). Levels of anti-IFX IgG Ab increased after reaction in the four patients with Ab prior to reinitiation.

Levels of anti-IFX IgG Ab following the reactions were significantly higher than in a comparable group of patients with Crohn's disease with maintained good clinical response to IFX maintenance therapy (median 0 U/ml, IQR 0-0 U/ml, n=59; $p<0.0001$), as well as in patients with loss of response to IFX maintenance therapy (median 35 U/ml, IQR 12-76 U/ml, n=26; $p=0.045$) as previously described.¹¹

1
2
3
4 Nineteen patients were tested for cross reactivity of anti-IFX Ab with ADA. All were negative.

5
6 A subset of 17 patients was later treated with ADA (median duration of treatment 177 days, IQR
7
8 56-770). All patients tolerated ADA without hypersensitivity reactions, except one. This patient
9
10 experienced a late reaction 12 days after the 1st ADA injection and blood sample 19 days after
11
12 reaction was highly positive for anti-ADA Ab (45 U/ml). Even though there was no
13
14 demonstrable cross-reactivity between the previously developed anti-IFX Ab and ADA, the
15
16 preexistence of low titers (below the detection limit) of cross reacting Ab below the detection
17
18 limit cannot be ruled out.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

The clinical significance of immunogenicity and the potential usefulness of anti-IFX Ab measurements in acute severe infusion reactions in IBD patients receiving IFX therapy are disputed.^{2;5;12} Several studies have reported a possible link between anti-IFX Ab and acute infusion reactions.¹³⁻¹⁶ The only study having addressed immunogenicity in patients with acute severe infusion reactions exclusively, found all patients with reactions anti-IFX Ab positive.⁶ Clinical resemblance with anaphylactic reactions suggests that some acute severe infusion reactions to IFX may be caused by a type 1 hypersensitivity reaction mediated by anti-IFX IgE Ab. In fact, an IgE mediated reaction to IFX has been reported in a child with Crohn's disease and in three patients with rheumatoid arthritis.^{17;18} A single study has examined the putative role of IgE Ab in acute infusion reactions to IFX in IBD patients, showing that serum tryptase levels were normal after reactions of which only four were severe.¹⁹ Tryptase is a mast cell enzyme and was used as a surrogate marker of IgE-mediated anaphylaxis; however, tryptase levels within the normal range do not exclude IgE mediated anaphylaxis, and other immunological mechanisms for reactions such as anti-IFX IgG Ab were not explored.^{5;20} The fact that many milder reactions abate by slowing the infusion seems to support the hypothesis that at least some reactions are not IgE mediated.^{2;21}

To systematically address the role of immunogenicity in acute severe infusion reactions in individual IBD patients, we measured anti-IFX IgG and IgE Ab after these reactions as well as prior to reinitiation of IFX after drug pauses. We found a clear association between reaction in the individual patients and development of high levels of circulating anti-IFX IgG Ab measured shortly after the reaction. In contrast, anti-IFX IgE Ab were not detected in any of these reactions. We conclude that the vast majority of acute severe infusion reactions to IFX are most likely not true anaphylactic reactions. Rather, they appear to be associated with anti-IFX IgG Ab. Our findings are supported by the previously published data from IBD patients as well as in line

1
2 with newly published hypotheses.⁵ Importantly, reactions could not be predicted by measuring
3
4 anti-IFX Ab prior to reinitiation of IFX after a drug pause. It remains to be tested if Ab
5
6 measurements following 1st infusion in a reinitiation series can help identify patients at risk of
7
8 reaction at the 2nd infusion.
9

10
11
12
13
14 The inability of previous studies to show a clear connection between anti-IFX Ab development
15
16 and acute severe infusion reactions may be due to inaccuracy of commonly used solid-phase
17
18 enzyme immunoassays (EIA), as these assays are sensitive to false negative test results due to
19
20 the inability to detect functionally monovalent immunoglobulins (IgG4), epitope masking, and to
21
22 inconclusive anti-IFX Ab measurements due to interference with IFX.^{11;22;23} We used a different
23
24 technique based on fluid-phase RIA which has been clinically validated in both IBD and
25
26 rheumatoid arthritis with high sensitivity and specificity.^{7-9;11;22} This RIA is not influenced to the
27
28 same degree by the potential artifacts encountered in solid-phase EIAs, it detects all isotypes of
29
30 immunoglobulins and all IgG subclasses binding to IFX, and there is little or no interference
31
32 with IFX. Time of IgE Ab measurement with respect to time of infusion reaction may be
33
34 important for the ability of all types of assays to detect anti-IFX IgE Ab, because false negative
35
36 results may occur if anti-IFX IgE Ab are bound to IFX at time of testing. To address this
37
38 potential bias, we also measured anti-IFX IgE Ab before reactions and at multiple time points
39
40 after reactions. Despite our assay being able to detect even low amounts of IgE Ab against a
41
42 birch pollen antigen, all tests for anti-IFX IgE Ab were negative.
43
44
45
46
47
48
49
50

51
52 Acute severe infusion reactions to IFX were observed in 8% of patients in our IBD cohort with a
53
54 substantially higher proportion of reactions during episodic treatment (17%) as compared to
55
56 continuous treatment (3%). Previously reported prevalence has varied from about 2% in
57
58 continuously treated patients up to 8.5% in episodically treated patients.^{6;13;14;24;25} Some
59
60 differences may be explained by the retrospective or prospective character of the data collection,

1
2 by the mean number of infusions per patient, and by the definition of the reactions. We defined
3
4 acute severe infusion reactions as reactions occurring during IFX infusion which were judged
5
6 severe by the treating physician, and resulting in immediate and permanent IFX cessation. This
7
8 is in accord with previous studies in which these reactions have been defined as acute reactions
9
10 leading to IFX discontinuation^{6;26}, acute reactions judged life-threatening^{13;24}, or acute reactions
11
12 leading to hospital admission³. The symptoms reported by our patients were similar to symptoms
13
14 reported in other studies.^{19;21} However, more restrictive definitions of reactions have been used,
15
16 and the fact that only two of our patients were treated with epinephrine may indicate, that the
17
18 severity of reactions in our cohort may be somewhat less than in other studies.²⁷
19
20
21
22
23
24
25

26 We also investigated potential risk factors associated with acute severe infusion reactions.
27
28 Episodic therapy defined as reinitiation of IFX after more than 12 weeks without therapy
29
30 strongly increased risk of reaction with an OR of 5, and it was the only factor associated with
31
32 increased risk in a multiple logistic regression analysis. In addition, we observed a longer period
33
34 between 1st and 2nd IFX series among episodically treated patients with reactions. A strong
35
36 association was also found in sensitivity analyses in which episodic therapy was defined as
37
38 reinitiation of IFX after 4 months (OR 6), and risk further increased when episodic therapy was
39
40 defined as reinitiation after 6 months (OR 8). Taken together, these data indicate that risk of
41
42 reactions increases with time between IFX series. Risk of reaction was highest at 2nd infusion in
43
44 a reinitiation series and particular high at 2nd infusion in the 2nd series. Previous studies have
45
46 reported a protective effect of induction regimen and scheduled maintenance therapy^{3;24},
47
48 increased risk after drug pause^{24;28;29}, and a tendency of higher frequency of reactions at the 2nd
49
50 IFX infusion^{3;19;24-26}. Reporting of the importance of concomitant immunosuppression has been
51
52 variable; some studies have found a protective effect^{3;6;13;25} while others have not^{26;30;31}. In
53
54 general, the previous studies have examined relatively small cohorts of acute and/or delayed
55
56 infusion reactions as a whole, and risk factors solely in patients with acute severe infusion
57
58
59
60

1
2 reactions have not been assessed. Thus, our study is the first reporting in a larger cohort of acute
3
4 severe infusion reactions only, and this is the first reporting of OR associated with increased risk
5
6 at IFX reinitiation as well as a statistically increased risk at 2nd infusion in 2nd treatment series.
7
8
9

10
11 In conclusion, acute severe infusion reactions to IFX appear not to be true IgE-mediated
12
13 anaphylactic reactions but rather associated with development of anti-IFX IgG Ab. Risk of
14
15 reaction is relatively high during episodic or reinitiation therapy, especially at the 2nd infusion in
16
17 a new series, but negative anti-IFX Ab before reinitiation does not exclude reactions.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Acknowledgements

The authors would like to thank Tobias Klausen for statistical assistance (Dept of Haematology, Herlev University Hospital, Denmark), and Charlotte Kühnel, Yvonne Krogager, Lene Neergaard, Lise Olsen, Anne Hallander, Anni Petersen, Vibeke Hansen, Hanne Fuglsang, and Birgit Kristensen for technical assistance (Dept of Medical Gastroenterology, Herlev University Hospital, Denmark).

Support for this study was provided by Aase and Ejnar Danielsen's Foundation, Beckett Foundation, Danish Biotechnology Program, Danish Colitis-Crohn Society, Danish Medical Association Research Foundation, Frode V. Nyegaard and wife's Foundation, Health Science Research Foundation of Region of Copenhagen, Herlev Hospital Research Council, Lundbeck Foundation, and P. Carl Petersens Foundation.

Table 1: Patient characteristics

Variables	Reaction n=25	No reaction n=290	P
Disease – no. (%)			
Crohn's disease / Fistulizing	21 / 6 (84) / (29)	197 / 84 (68) / (43)	0.095
Ulcerative colitis	4 (16)	93 (32)	
Male sex – no. (%)	10 (40)	146 (50)	0.321
Age at diagnosis – yr median (IQR)	19 (15-29)	26 (20-37)	0.013
Age at 1 st IFX infusion – yr median (IQR)	28 (19-35)	35 (26-45)	0.012
Disease duration at 1 st IFX series – yr median (IQR)	5 (2-8)	5 (2-11)	0.620
IFX infusions – no. median (IQR)	5 (5-9)	5 (3-10)	0.543
IFX dosing – no. (%)			
5 mg/kg	24 (96)	288 (99)	0.220
10 mg/kg	1 (4)	2 (1)	
IFX regimen – no. (%)			
Continuous	7 (28)	200 (69)	<0.001
Episodic	18 (72)	90 (31)	
Concomitant immunosuppression* at last IFX series – no. (%)	14 (56)	188 (65)	0.377
<i>Variables assessed only in episodically treated patients:</i>			
Patients having received 2 nd IFX series – no. (%)	18 (72)	90 (31)	<0.001
Time period 1 st to 2 nd IFX series – days median (IQR)	861 (286-1728)	211 (146-458)	<0.001
Patients having received 3 rd IFX series – no. (%)	2 (8)	24 (8)	1.000
Time period 2 nd to 3 rd IFX series – days median (IQR)	1608 (375-2841)	220 (155-767)	0.124
Patients having received 4 th IFX series – no. (%)	1 (4)	5 (2)	0.424
Time period 3 rd to 4 th IFX series – days median (IQR)	329 (NA)	526 (203-1092)	0.770

* Azathioprine, mercaptopurine, or methotrexate.

IFX: Infliximab

IQR: Interquartile range

NA: Not applicable

FIGURE LEGENDS**Figure 1**

Risk of acute severe infusion reactions to infliximab (IFX) during continuous and episodic therapy.

Figure 2

Distribution of acute severe infusion reactions to infliximab (IFX) during 1st and 2nd IFX series.

Figure 3

Anti-infliximab (IFX) IgG antibodies (Ab) in individual patients before reinitiation of IFX and after acute severe infusion reactions. Samples from the same patients are connected by dotted lines.



Figure 1


Figure 2



Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 3



Reference List

- 1
2
3
4
5
6 (1) Clark M, Colombel JF, Feagan BC et al. American gastroenterological association
7
8 consensus development conference on the use of biologics in the treatment of
9
10 inflammatory bowel disease, June 21-23, 2006. *Gastroenterology* 2007;133:312-339.
11
- 12 (2) Miehsler W, Novacek G, Wenzl H et al. A decade of infliximab: The Austrian evidence
13
14 based consensus on the safe use of infliximab in inflammatory bowel disease. *J Crohns*
15
16 *Colitis* 2010;4:221-256.
17
- 18 (3) Fidder H, Schnitzler F, Ferrante M et al. Long-term safety of infliximab for the treatment
19
20 of inflammatory bowel disease: a single-centre cohort study. *Gut* 2009;58:501-508.
21
22
- 23 (4) Vermeire S, Van AG, Rutgeerts P. Serum sickness, encephalitis and other complications
24
25 of anti-cytokine therapy. *Best Pract Res Clin Gastroenterol* 2009;23:101-112.
26
27
- 28 (5) Maggi E, Vultaggio A, Matucci A. Acute infusion reactions induced by monoclonal
29
30 antibody therapy. *Expert Rev Clin Immunol* 2011;7:55-63.
31
32
- 33 (6) Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous
34
35 hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a
36
37 randomized controlled trial. *Gastroenterology* 2003;124:917-924.
38
39
- 40 (7) Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T.
41
42 Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid
43
44 arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
45
46 *Arthritis Rheum* 2006;54:3782-3789.
47
48
- 49 (8) Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-
50
51 TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab
52
53 antibodies. *Rheumatology* 2007;46:1828-1834.
54
55
- 56 (9) Radstake TR, Svenson M, Eijsbouts AM et al. Formation of antibodies against infliximab
57
58 and adalimumab strongly correlates with functional drug levels and clinical responses in
59
60 rheumatoid arthritis. *Ann Rheum Dis* 2009;68:1739-1745.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- (10) Svenson M, Jacobi HH, Bodtger U, Poulsen LK, Rieneck K, Bendtzen K. Vaccination for birch pollen allergy. Induction of affinity-matured or blocking IgG antibodies does not account for the reduced binding of IgE to Bet v 1. *Mol Immunol* 2003;39:603-612.
 - (11) Steenholdt C, Bendtzen K, Brynskov J, Thomsen OO, Ainsworth MA. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. *Scand J Gastroenterol* 2010.
 - (12) Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. *Inflamm Bowel Dis* 2009;15:1264-1275.
 - (13) Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. *Clin Gastroenterol Hepatol* 2004;2:542-553.
 - (14) Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn's disease. *N Engl J Med* 2004;350:876-885.
 - (15) Ben-Horin S, Yavzori M, Katz L et al. The immunogenic part of infliximab is the F(ab')₂, but measuring antibodies to the intact infliximab molecule is more clinically useful. *Gut* 2011;60:41-48.
 - (16) Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. *N Engl J Med* 2003;348:601-608.
 - (17) Candon S, Mosca A, Ruemmele F, Goulet O, Chatenoud L, Cezard JP. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. *Clin Immunol* 2006;118:11-19.
 - (18) Vultaggio A, Matucci A, Nencini F et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. *Allergy* 2010;65:657-661.

- 1
2 (19) Cheifetz A, Smedley M, Martin S et al. The incidence and management of infusion
3 reactions to infliximab: a large center experience. *Am J Gastroenterol* 2003;98:1315-
4 1324.
5
6
7
8
9 (20) Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food
10 in children and adolescents. *N Engl J Med* 1992;327:380-384.
11
12
13 (21) Duburque C, Lelong J, Iacob R et al. Successful induction of tolerance to infliximab in
14 patients with Crohn's disease and prior severe infusion reactions. *Aliment Pharmacol*
15 *Ther* 2006;24:851-858.
16
17
18 (22) Bendtzen K, Ainsworth M, Steenholdt C, Thomsen OO, Brynskov J. Individual medicine
19 in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and
20 immunogenicity of anti-tumour necrosis factor-alpha antibodies. *Scand J Gastroenterol*
21 2009;44:774-781.
22
23
24 (23) Hennig C, Rink L, Fagin U, Jabs WJ, Kirchner H. The influence of naturally occurring
25 heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins
26 using sandwich ELISAs. *J Immunol Methods* 2000;235:71-80.
27
28
29 (24) Kugathasan S, Levy MB, Saeian K et al. Infliximab retreatment in adults and children
30 with Crohn's disease: risk factors for the development of delayed severe systemic
31 reaction. *Am J Gastroenterol* 2002;97:1408-1414.
32
33
34 (25) Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents:
35 frequency, outcome and a predictive model. *Aliment Pharmacol Ther* 2003;17:75-84.
36
37
38 (26) Colombel JF, Loftus EV, Jr., Tremaine WJ et al. The safety profile of infliximab in
39 patients with Crohn's disease: the Mayo clinic experience in 500 patients.
40 *Gastroenterology* 2004;126:19-31.
41
42
43 (27) Breynaert C, Ferrante M, Fidler H et al. Tolerability of Shortened Infliximab Infusion
44 Times in Patients With Inflammatory Bowel Diseases: A Single-Center Cohort Study.
45 *Am J Gastroenterol* 2011.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- (28) Margo F, Marques M, Santos CC. Episodic infliximab treatment induces infusion reactions. *Inflamm Bowel Dis* 2008;14:1608-1610.
- (29) Rutgeerts P, Feagan BG, Lichtenstein GR et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. *Gastroenterology* 2004;126:402-413.
- (30) Lees CW, Ali AI, Thompson AI et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. *Aliment Pharmacol Ther* 2009;29:286-297.
- (31) Zabana Y, Domenech E, Manosa M et al. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice. *Aliment Pharmacol Ther* 2010;31:553-560.

DECLARATION OF INTERESTS

Sources of financial support the last two years must be acknowledged.

1. Authors' declaration of personal interests:

(i) Klaus Bendtzen has served as a speaker for Pfizer, Wyeth, Roche, Bristol-Meyers Squibb, and Biomonitor A/S.

Ole Østergaard Thomsen has served as a speaker and consultant for Schering-Plough, UCB, and Zealand Pharma.

(ii) Morten Svenson is an employee at Biomonitor A/S.

(iii) Klaus Bendtzen owns stocks in Biomonitor A/S.

Casper Steenholdt, Jørn Brynskov, and Mark Ainsworth have no personal interests to declare.

2. Declaration of funding interests:

This study was funded by independent research grants from: Aase and Ejnar Danielsen's Foundation, Beckett Foundation, Danish Biotechnology Program, Danish Colitis-Crohn Society, Danish Medical Association Research Foundation, Frode V. Nyegaard and wife's Foundation, Health Science Research Foundation of Region of Copenhagen, Herlev Hospital Research Council, Lundbeck Foundation, and P. Carl Petersens Foundation.